Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2020; 11(8): 644-654
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.644
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.644
Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports
Lisa BE Shields, Norton Neuroscience Institute, Norton Healthcare, Louisville, KY 40202, United States
Arash Rezazadeh Kalebasty, Norton Cancer Institute, Norton Healthcare, Louisville, KY 40202, United States
Author contributions: Shields LBE and Kalebasty AR contributed to the conception, design, acquisition, analysis, and interpretation of data; Shields LBE drafted the manuscript; Shields LBE and Kalebasty AR critically revised the manuscript and gave final approval.
Informed consent statement: All patients in this case series provided informed consent for treatment. Several patients died due to complications of their cancer before this case series was written.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Arash Rezazadeh Kalebasty, MD, Doctor, Norton Cancer Institute, Norton Healthcare, 315 East Broadway, Louisville, KY 40202, United States. arez@uci.edu
Received: January 17, 2020
Peer-review started: January 17, 2020
First decision: March 5, 2020
Revised: May 21, 2020
Accepted: June 27, 2020
Article in press: June 27, 2020
Published online: August 24, 2020
Processing time: 212 Days and 3.9 Hours
Peer-review started: January 17, 2020
First decision: March 5, 2020
Revised: May 21, 2020
Accepted: June 27, 2020
Article in press: June 27, 2020
Published online: August 24, 2020
Processing time: 212 Days and 3.9 Hours
Core Tip
Core tip: Renal cell carcinoma (RCC) and hematologic malignancies (HM) in the same patient is rare. We report the common characteristics of 9 patients diagnosed with concurrent RCC and HM and their clinical course and treatment response. None of the patients was treated with cytotoxic chemotherapy or radiation between the diagnosis of RCC and HM. Several features in our series strengthen the immune dysregulation theory as the likely mechanism. Long-term medical surveillance is warranted when a patient is diagnosed with RCC or HM. Clinicians should be aware that either of these conditions may be diagnosed first or they may be diagnosed simultaneously.